Progression to cirrhosis in hepatitis C patients: an age-dependent process (Q42168870)

17 October 2017

Progression to cirrhosis in hepatitis C patients: an age-dependent process (English)

1 reference

17 October 2017

0 references

1 reference

Pierre-François Pradat

1

object named as

Pierre Pradat

1 reference

17 October 2017

Nicolas Voirin

2

1 reference

17 October 2017

Hans Ludger Tillmann

3

1 reference

17 October 2017

Michèle Chevallier

4

1 reference

17 October 2017

Christian Trépo

5

1 reference

17 October 2017

1 April 2007

1 reference

17 October 2017

1 reference

17 October 2017

27

1 reference

17 October 2017

3

1 reference

17 October 2017

335-339

1 reference

Hepatitis B and hepatitis C viruses in liver transplantation

17 October 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

45-year follow-up of hepatitis C virus infection in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

The natural history of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Factors predicting progression to cirrhosis and hepatocellular carcinoma in patients with transfusion-associated hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C--a study of 527 patients at one establishment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Merging models of hepatitis C virus pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

T-cell dysregulation caused by chronic antigenic stress: the role of CMV in immunosenescence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Human immunosenescence: does it have an infectious component?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Recurrence of hepatitis C infection: Where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Factors that influence the severity of recurrent hepatitis c virus following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Infection with GB virus C and reduced mortality among HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Factors influencing the rate of fibrosis progression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01430.X

10.1111/J.1478-3231.2006.01430.X

21 January 2018

Identifiers

DOI

1 reference

17 October 2017

1 reference